On 11 September 2019, Merck KGaA (Darmstadt, Germany) announced that the FDA had granted a breakthrough therapy designation to TEP (TepmetkoTM) for the management of patients with non-small cell lung cancers (NSCLC) harboring an MET exon 14 skipping alteration who have progressed subsequent platinum-based therapy [1]. Here, MET is linked to non-small cell lung carcinoma.